| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 22,298 | 19,062 |
| Net change in cash and cash equivalents and restricted cash | -37,403 | -22,886 |
| Cash and cash equivalents at beginning of period | 85,510 | - |
| Cash and cash equivalents at end of period | 48,107 | - |
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)